BNB Plus Corp., established in 1983 and based in Stony Brook, NY, is a biotechnology firm dedicated to pioneering and commercializing technologies for the synthesis and identification of both deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). The company's operations are divided into three distinct business segments. Its Therapeutic DNA Production Services division specializes in the enzymatic manufacturing of synthetic DNA, used in the creation of nucleic acid-based treatments, and also develops and markets its proprietary RNA Polymerase (RNAP) for mRNA therapeutic production. The MDx Testing Services segment concentrates on developing clinical molecular diagnostic and genetic assessments, in addition to providing comprehensive clinical laboratory testing services. Lastly, the DNA Tagging and Security Products and Services segment leverages DNA detection techniques for securing industrial supply chains and offering various security solutions.
BNB Plus Corp. (BNBX) Announces Transition to Fully Internalized Digital Asset Treasury Management
BNB Plus Corp. is ending its advisory and asset management arrangement with Cypress Management, LLC to bring the execution of its BNB treasury strategy fully in-house.
CEO Clay Shorrock stated that the move tightens alignment between strategy and execution, marking a milestone following recent shareholder-led financing.
The company detailed the transition arrangements in a Form 8-K filed on July 29, 2026.